These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 11161856

  • 21. Surgical risk-reduction in carriers of BRCA mutations: where do we go from here?
    Kauff ND, Barakat RR.
    Gynecol Oncol; 2004 May; 93(2):277-9. PubMed ID: 15099933
    [No Abstract] [Full Text] [Related]

  • 22. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
    Olivier RI, van Beurden M, Lubsen MA, Rookus MA, Mooij TM, van de Vijver MJ, van't Veer LJ.
    Br J Cancer; 2004 Apr 19; 90(8):1492-7. PubMed ID: 15083174
    [Abstract] [Full Text] [Related]

  • 23. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
    Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K.
    N Engl J Med; 2002 May 23; 346(21):1609-15. PubMed ID: 12023992
    [Abstract] [Full Text] [Related]

  • 24. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens.
    Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ.
    Eur J Cancer; 2013 Jan 23; 49(1):132-41. PubMed ID: 22921157
    [Abstract] [Full Text] [Related]

  • 25. Occult fallopian tube cancer in a patient with BRCA1 breast cancer.
    Brown JV, Epstein HD, Mattison JN, Micha JP, Rettenmaier MA, Goldstein BH.
    J Minim Invasive Gynecol; 2008 Jan 23; 15(6):749-51. PubMed ID: 18971141
    [Abstract] [Full Text] [Related]

  • 26. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol.
    Rabban JT, Krasik E, Chen LM, Powell CB, Crawford B, Zaloudek CJ.
    Am J Surg Pathol; 2009 Dec 23; 33(12):1878-85. PubMed ID: 19898224
    [Abstract] [Full Text] [Related]

  • 27. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
    Tobias DH, Eng C, McCurdy LD, Kalir T, Mandelli J, Dottino PR, Cohen CJ.
    Gynecol Oncol; 2000 Aug 23; 78(2):148-51. PubMed ID: 10926794
    [Abstract] [Full Text] [Related]

  • 28. Risk of endometrial carcinoma associated with BRCA mutation.
    Levine DA, Lin O, Barakat RR, Robson ME, McDermott D, Cohen L, Satagopan J, Offit K, Boyd J.
    Gynecol Oncol; 2001 Mar 23; 80(3):395-8. PubMed ID: 11263938
    [Abstract] [Full Text] [Related]

  • 29. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.
    Cancer; 2006 Dec 15; 107(12):2745-51. PubMed ID: 17109443
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Single-port risk-reducing salpingo-oophorectomy with and without hysterectomy: surgical outcomes and learning curve analysis.
    Escobar PF, Starks DC, Fader AN, Barber M, Rojas-Espalliat L.
    Gynecol Oncol; 2010 Oct 15; 119(1):43-7. PubMed ID: 20579712
    [Abstract] [Full Text] [Related]

  • 34. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.
    Maehle L, Apold J, Paulsen T, Hagen B, Løvslett K, Fiane B, Van Ghelue M, Clark N, Møller P.
    Clin Cancer Res; 2008 Nov 15; 14(22):7569-73. PubMed ID: 19010876
    [Abstract] [Full Text] [Related]

  • 35. BRCA: the breast, ovarian, and other cancer genes.
    Boyd J.
    Gynecol Oncol; 2001 Mar 15; 80(3):337-40. PubMed ID: 11263927
    [No Abstract] [Full Text] [Related]

  • 36. Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense?
    Olivier RI, Lubsen-Brandsma LA, van Boven H, van Beurden M.
    Gynecol Oncol; 2005 Feb 15; 96(2):439-43. PubMed ID: 15661233
    [Abstract] [Full Text] [Related]

  • 37. Familial ovarian cancer.
    Elit L.
    Can Fam Physician; 2001 Apr 15; 47():778-84. PubMed ID: 11340759
    [Abstract] [Full Text] [Related]

  • 38. Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy.
    Powell CB.
    Gynecol Oncol; 2006 Jan 15; 100(1):1-2. PubMed ID: 16368438
    [No Abstract] [Full Text] [Related]

  • 39. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations.
    Levine DA, Argenta PA, Yee CJ, Marshall DS, Olvera N, Bogomolniy F, Rahaman JA, Robson ME, Offit K, Barakat RR, Soslow RA, Boyd J.
    J Clin Oncol; 2003 Nov 15; 21(22):4222-7. PubMed ID: 14615451
    [Abstract] [Full Text] [Related]

  • 40. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
    Machácková E, Foretová L, Navrátilová M, Valík D, Claes K, Messiaen L.
    Cas Lek Cesk; 2000 Oct 11; 139(20):635-7. PubMed ID: 11192759
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.